NCT06630130View on ClinicalTrials.gov

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

October 30, 2028

Study Completion Date

June 30, 2029

Conditions
Stomach Neoplasms
Interventions
DRUG

Trastuzumab deruxtecan

"* Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)"

DRUG

Capecitabine

"* Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"

DRUG

Rilvegostomig

"(Only Cohort B)~* Neoadjuvant; Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months)"

All Listed Sponsors
lead

Jeeyun Lee

OTHER

NCT06630130 - Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer | Biotech Hunter | Biotech Hunter